Cardax, Inc.
OTC: CDXI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David G. Watumull
- Employees
- 10
- Headquarters
- Honolulu, United States
- IPO year
- 2013
- Market cap
- $80.0
- Website
- https://www.cardaxpharma.com
Loading CDXI…
Loading profile data…Frequently asked questions about CDXI
What does Cardax, Inc. (CDXI) do?
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation,...
Where does CDXI trade?
Cardax, Inc. (CDXI) trades on the Other OTC.
What sector is CDXI in?
Cardax, Inc. (CDXI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cardax, Inc.?
David G. Watumull is the chief executive officer of Cardax, Inc. (CDXI).
Where is Cardax, Inc. headquartered?
Cardax, Inc. is headquartered in United States.
Does CDXI pay a dividend?
Cardax, Inc. (CDXI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CDXI go public?
Cardax, Inc. (CDXI) completed its initial public offering in 2013.